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ABSTRACT
Background: The connection between corti-
cotherapy and neuropsychiatric symptoms is 
widely known, being one of the first questions 
we need to assess when presenting with first 
episode psychiatric symptoms or confusional 
state. 
Aims: To date, data on cases related to inhaled 
corticotherapy and neuropsychiatric effects is 
scarce. In this paper we describe a rare case in 
a young woman.
Methods: The clinical case presented led us 
to try to understand the data published on the 
subject in order to discuss it in greater length.
Results and Conclusions: We present and 
discuss a 27-year-old patient’s case, with no 
previous psychiatric disease, who was admit-
ted to our Psychiatric ward after the onset of 
severe acute behavioural disturbance charac-
terized by aggressiveness, visual and auditory 
hallucinatory activity, misidentification and 
altered conscience status. It was later found 
that seven days earlier she had been prescribed 
inhaled corticotherapy for a minor respiratory 
infection. A few days after corticotherapy wi-
thdrawal, the clinical symptoms improved sig-
nificantly. 
Key-Words: Delirium; Steroids; Inhaled The-
rapeutics; Iatrogenic; Side Effects.
RESUMO
Introdução: A relação entre corticoterapia 
e sintomas neuropsiquiátricos é sobeja-
mente conhecida, sendo uma das primeiras 
questões a colocar face a uma apresentação 
inaugural com sintomas psiquiátricos ou 
estado confusional.
Objetivos: A apresentação de um quadro 
de Delirium secundário à administração de 
terapêutica corticoide inalada é aqui descri-
ta pela primeira vez num paciente jovem. 
Métodos: O caso clínico aqui apresentado 
levou-nos a tentar entender os dados publi-
cados sobre o assunto no sentido de melhor 
o compreender e discutir.
Resultados e Conclusões: Apresentamos 
e discutimos o caso de uma doente de 27 
anos, sem história de doença psiquiátrica, 
internada após episódio agudo de alteração 
grave de comportamento com heteroagres-
sividade, atividade alucinatória auditiva e 
visual, falsos reconhecimentos e alteração 
do estado de consciência. Retrospetivamente 
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pode-se apurar inicio de terapêutica corti-
coide na forma inalada há 7 dias por um 
quadro infecioso respiratório. Após retirada 
dos corticoides ocorreu melhoria significati-
va do quadro ao fim de poucos dias. 
Palavras-Chave: Delirium; Corticoides; 
Nebulizadores e Vaporizadores; Iatrogenia; 
Efeitos Colaterais e Reações Adversas Rela-
cionadas com Fármacos.
CASE PRESENTATION
The patient is a 27-year-old single female, 
living with her foster parents. She has com-
pleted 12 years of school and is currently em-
ployed at a woodwork shop. She was presen-
ted at the Emergency Room (ER) of her local 
hospital after a preceding two-day behaviou-
ral disturbance. The patient had become agi-
tated at home, destroying her belongings in 
her own room where she had locked herself 
in, afraid of her own parents, presumably be-
cause of hallucinatory activity and misiden-
tifications. 
From her background we could only point out 
a history of syphilis in her infancy (without 
any current laboratory or clinical features), 
no regular prescription drugs and this was her 
first contact with mental health services.
She had been prescribed inhaled corticothe-
rapy - salmeterol and fluticasone propiona-
te 250/50 mcg/dose every twelve hours - for 
flu-like symptoms (cough and malaise). For 
about seven days she overused it, taking it 
about once per hour.
A state of fluctuating consciousness, disorga-
nized speech sometimes incomprehensible, 
irritability and restlessness, developed pro-
gressively over the eight days since she had 
begun the steroids. At that time she presented 
with psychomotor agitation with heteroag-
gressiveness, visual and auditory hallucina-
tions and misidentification - she believed she 
saw her grandparents in her parent’s bodies. 
The next day she was evaluated at the ER for 
these behavioural symptoms. She was given 1g 
acetaminophen intravenous (IV), fluids and a 
new dosage of 1mg inhaled budesonide for her 
persisting cough before she was evaluated by 
Neurology and Psychiatry.
The laboratory and imaging study was per-
formed with complete blood count, basic bio-
chemistry, chest x-ray and head computed to-
mography scan (CT) – with no clinical signs 
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Figure 1. Timeline.
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of a cause for the presenting complaints. The 
patient also performed a urine test for abusive 
drug consumption which turned out negative 
for all the substances searched. Therefore, the 
attending physicians felt that an adequate ex-
clusion of organic disease had been performed 
and requested a psychiatric evaluation.
Attending to the presenting behavioural 
changes with aggressiveness, attention and 
consciousness disorders, hallucinatory acti-
vity and misidentification, she was voluntary 
admitted to a psychiatric ward for further 
clinical investigation and treatment. The 
patient stopped using inhaled corticotherapy 
and was started on an atypical antipsychotic 
(olanzapine 10 mg per day). From this point 
on, the hallucinatory activity and misidenti-
fications ceased.
As an inpatient she completed the laboratory 
tests with virological and syphilis markers, 
thyroid function tests, B12 vitamin and folic 
acid dosing. All of these were also innocent 
except for a minor folic acid deficit. After dis-
charge the patient underwent a psychological 
assessment which determined a minor intel-
lectual impairment.
During her stay at our inpatient unit she 
maintained a generally calm and orderly 
behaviour, a healthy interaction with health 
care professionals and other patients, notwi-
thstanding a puerile posture. Initially she was 
a little restless but she was able to focus and 
maintain attention, always awake and was 
fully oriented to self, as well as time and space, 
without any behaviour that would suggest she 
was experiencing delusional or hallucinatory 
activity. The insight into the hallucinatory 
phenomena previous to her admission was 
addressed but, probably due to her cultural 
background and her intellectual disability, full 
insight was not achieved. 
The patient was discharged home, seven 
days after admission, with a clinical diag-
nosis of acute hyperactive delirium indu-
ced by propionate of fluticasone (according 
to the Diagnostic and Statistical Manual of 
Mental Disorders, Fifth Edition2). She was 
maintained on olanzapine 10 mg/day until 
her first outpatient appointment a month 
later. By that time, she presented complaints 
of somnolence and weight gain, without any 
psychiatric symptoms so it was decided to 
discontinue olanzapine. The patient was also 
advised to abstain from the use of any type 
of corticotherapy as it is known that after an 
episode of neuropsychiatric illness induced 
by corticotherapy, the risk of recurrence is 
present with new usage3.
DISCUSSION AND CONCLUSIONS
The case here reported refers to a 27-year-old 
woman, with no previous psychiatric history, 
presenting an acute episode (around two days 
evolution) of aggressiveness, agitation, fluc-
tuating consciousness, visual and auditory 
hallucinatory activity and misidentification.
After an organic screening with blood tests 
and head CT scan, a psychiatric aetiology was 
assumed despite several clues to a possible 
organic origin (first episode, acute presenta-
tion, altered mental status, visual hallucina-
tions, misidentification and recent infection). 
After a careful revision of the case, it came to 
our attention that the patient had recently 
started inhaled therapeutics for a minor res-
piratory infection - salmeterol and fluticaso-
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ne propionate 250/50 mcg/dose every twelve 
hours – and also that she had been using it 
in a much higher dose than prescribed. 
Currently, it is widely known that steroid the-
rapy is associated with delirium, depression, 
mania, psychosis and cognitive impairment4. 
A study of 261272 patients on steroid thera-
py, matched by gender and age with patients 
with the same types of medical disease, but 
no corticotherapy, were accessed for diffe-
rent neuropsychiatric presentations during 
a three-month period revealing a 5.14 Odds 
Ratio (IC 95% - 4.54 a 5,82) for delirium, 
confusion or maze3. Only recently did we 
start to understand the mechanisms un-
derlying these neuropsychiatric symptoms. 
Cortisol is the end product of the hypothala-
mic-pituitary-adrenal (HPA) axis and it has 
two different receptors widely distributed in 
the brain especially in the hypothalamus, pi-
tuitary gland and hippocampus– mineralo-
corticoid and glucocorticoid – the first being 
implicated in appraisal processes and the on-
set of stress reactions and the second in ter-
minating the stress response3,4. There seems 
to be a connection between steroid responses 
in the brain and other neurotransmitter sys-
tems1, namely the dopamine, acetylcholine 
and also the serotoninergic system which is 
strongly implicated in mood, cognition and 
behaviour4. Synthetic steroids preferentially 
activate glucocorticoid receptors while also 
depleting (by means of negative feedback) 
the adrenal cortisol secretion. Therefore, an 
extreme imbalance between glucocorticoid 
receptors and mineralocorticoid receptors 
caused by the exogenous steroid can cause 
cognitive impairment, disturbed emotions 
and other neuropsychiatric manifestations3. 
There is evidence that, in prolonged high do-
sages, various forms of neural damage can 
also explain these symptoms3. There is still 
much to be known about these mechanisms 
as they appear to be complex and unpredic-
table.
Inhalatory use is generally associated with 
a small systemic dosage, but in this case, it 
seems that higher doses reached the lung tis-
sue (and the gastro-intestinal tract by unin-
tentional swallowing) and the bloodstream 
as consequence of an excessive intake. This is 
very important as the risk for neuropsychia-
tric disturbances is associated with the dosa-
ge of corticotherapy3.
The clinical improvement about three days 
after corticoid withdrawal supports the 
hypothesis of an iatrogenic cause. Likewise, 
the clinical deterioration after a dosage of 
budesonide at the ER makes this hypothesis 
very likely. However, this was also the mo-
ment when an atypical antipsychotic drug 
was started. Using the Naranjo Scale – a sca-
le used to access the likelihood of an adver-
se reaction being associated with a specific 
drug – a probable association was stablished 
(6 out of 13)6. The previous infection history 
may also have been a risk factor for a con-
fusional state. The other drug used – salme-
terol - is a long acting beta-2 agonist used 
as a bronchodilator; we found no evidence to 
associate its use to psychiatric disturbances 
or confusional syndromes.
Confusional states usually present with psy-
chiatric-like symptoms, but the presentation 
of altered mental status, even a hyperactive 
one, together with the patient’s recent clini-
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cal history should have raised the possibility 
of a non-psychiatric cause for her symptoms. 
The screening for organic causes of beha-
vioural changes should be made whilst com-
pleting the patient’s medical history, together 
with a physical examination and directed 
auxiliary study. There are several factors 
associated with confusional states7: patients 
characteristics such as age, gender, isolation, 
alcohol and tobacco use; chronic disease as 
cardiac or respiratory disease or cognitive 
impairment; environment issues such as ad-
mission through the ER, physical restraint, 
absence of time markers; acute disease with 
fever, sedation, and changes in food intake. 
This case highlights the clinical significance 
of obtaining a careful medical history, espe-
cially in a person with no apparent previous 
psychiatric history presenting with sudden 
and acute behavioural disturbance. 
When presented with a case of delirium, 
the main strategy should be to identify the 
causing or underlying factors in order to 
remove them. In this case, the interruption 
of the inhaled corticotherapy seems to have 
been crucial for the clinical outcome. Trea-
ting behavioural changes, secondary to a 
confusional state should be made with low 
dosage haloperidol or an atypical antipsyco-
tic7. These two options seem to have similar 
outcomes, except in the need for higher do-
ses where haloperidol shows increased ex-
trapyramidal symptoms. These drugs aim to 
reduce any risks for the patient and others, 
mechanical restraint should be used as a last 
resort and only for the shortest time possible.
The connection between oral corticotherapy 
and neuropsychiatric symptoms has already 
been established3, however, in this case the 
use of inhaled corticotherapy seems to have 
caused a confusional state. Therefore, espe-
cially in patients with risk factors for con-
fusional states, it seems important that this 
connection should be considered.
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